250 related articles for article (PubMed ID: 16889231)
21. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
Wang Y; Trepel JB; Neckers LM; Giaccone G
Curr Opin Investig Drugs; 2010 Dec; 11(12):1466-76. PubMed ID: 21154128
[TBL] [Abstract][Full Text] [Related]
22. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
23. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
[TBL] [Abstract][Full Text] [Related]
24. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
He H; Zatorska D; Kim J; Aguirre J; Llauger L; She Y; Wu N; Immormino RM; Gewirth DT; Chiosis G
J Med Chem; 2006 Jan; 49(1):381-90. PubMed ID: 16392823
[TBL] [Abstract][Full Text] [Related]
25. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G
Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
[TBL] [Abstract][Full Text] [Related]
26. Hsp90 as a therapeutic target in patients with oesophageal carcinoma.
Ekman S; Bergqvist M; Tell R; Bergström S; Lennartsson J
Expert Opin Ther Targets; 2010 Mar; 14(3):317-28. PubMed ID: 20148718
[TBL] [Abstract][Full Text] [Related]
27. F1F0-ATP synthase functions as a co-chaperone of Hsp90-substrate protein complexes.
Papathanassiu AE; MacDonald NJ; Bencsura A; Vu HA
Biochem Biophys Res Commun; 2006 Jun; 345(1):419-29. PubMed ID: 16682002
[TBL] [Abstract][Full Text] [Related]
28. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
Martins AS; Ordoñez JL; García-Sánchez A; Herrero D; Sevillano V; Osuna D; Mackintosh C; Caballero G; Otero AP; Poremba C; Madoz-Gúrpide J; de Alava E
Cancer Res; 2008 Aug; 68(15):6260-70. PubMed ID: 18676850
[TBL] [Abstract][Full Text] [Related]
29. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
[TBL] [Abstract][Full Text] [Related]
30. Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines.
Håvik B; Bramham CR
Oncol Rep; 2007 Jun; 17(6):1501-10. PubMed ID: 17487411
[TBL] [Abstract][Full Text] [Related]
31. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
Wright L; Barril X; Dymock B; Sheridan L; Surgenor A; Beswick M; Drysdale M; Collier A; Massey A; Davies N; Fink A; Fromont C; Aherne W; Boxall K; Sharp S; Workman P; Hubbard RE
Chem Biol; 2004 Jun; 11(6):775-85. PubMed ID: 15217611
[TBL] [Abstract][Full Text] [Related]
32. A time-resolved fluorescence resonance energy transfer-based HTS assay and a surface plasmon resonance-based binding assay for heat shock protein 90 inhibitors.
Zhou V; Han S; Brinker A; Klock H; Caldwell J; Gu XJ
Anal Biochem; 2004 Aug; 331(2):349-57. PubMed ID: 15265741
[TBL] [Abstract][Full Text] [Related]
33. Structural studies on the co-chaperone Hop and its complexes with Hsp90.
Onuoha SC; Coulstock ET; Grossmann JG; Jackson SE
J Mol Biol; 2008 Jun; 379(4):732-44. PubMed ID: 18485364
[TBL] [Abstract][Full Text] [Related]
34. ATPase inhibitors of heat-shock protein 90, second season.
Janin YL
Drug Discov Today; 2010 May; 15(9-10):342-53. PubMed ID: 20230904
[TBL] [Abstract][Full Text] [Related]
35. Hsp90: the vulnerable chaperone.
Chiosis G; Vilenchik M; Kim J; Solit D
Drug Discov Today; 2004 Oct; 9(20):881-8. PubMed ID: 15475321
[TBL] [Abstract][Full Text] [Related]
36. Potent triazolothione inhibitor of heat-shock protein-90.
Feldman RI; Mintzer B; Zhu D; Wu JM; Biroc SL; Yuan S; Emayan K; Chang Z; Chen D; Arnaiz DO; Bryant J; Ge XS; Whitlow M; Adler M; Polokoff MA; Li WW; Ferrer M; Sato T; Gu JM; Shen J; Tseng JL; Dinter H; Buckman B
Chem Biol Drug Des; 2009 Jul; 74(1):43-50. PubMed ID: 19519743
[TBL] [Abstract][Full Text] [Related]
37. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.
Bussenius J; Blazey CM; Aay N; Anand NK; Arcalas A; Baik T; Bowles OJ; Buhr CA; Costanzo S; Curtis JK; DeFina SC; Dubenko L; Heuer TS; Huang P; Jaeger C; Joshi A; Kennedy AR; Kim AI; Lara K; Lee J; Li J; Lougheed JC; Ma S; Malek S; Manalo JC; Martini JF; McGrath G; Nicoll M; Nuss JM; Pack M; Peto CJ; Tsang TH; Wang L; Womble SW; Yakes M; Zhang W; Rice KD
Bioorg Med Chem Lett; 2012 Sep; 22(17):5396-404. PubMed ID: 22877636
[TBL] [Abstract][Full Text] [Related]
38. HSP90 inhibitors: current development and potential in cancer therapy.
Sidera K; Patsavoudi E
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
[TBL] [Abstract][Full Text] [Related]
39. Inside the Hsp90 inhibitors binding mode through induced fit docking.
Lauria A; Ippolito M; Almerico AM
J Mol Graph Model; 2009 Feb; 27(6):712-22. PubMed ID: 19084447
[TBL] [Abstract][Full Text] [Related]
40. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
